Mark Lipstein

Title: Innovations in Cancer Treatment by Mark Lipstein

Introduction

Mark Lipstein is an accomplished inventor based in New York, NY (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of new compounds. His work focuses on reducing c-Myc expression, which is crucial in the treatment of hematological cancers.

Latest Patents

Mark Lipstein holds a patent for "Compounds for reducing c-Myc in c-Myc overexpressing cancers." This invention relates to new compounds that effectively reduce c-Myc expression, making them useful for treating aggressive B- and T-cell lymphomas. The compounds can be combined with adjunct c-Myc inhibitor agents, such as PI3K inhibitors, CK-1 inhibitors, Akt-inhibitors, proteasome inhibitors, and mTor inhibitors. The c-Myc reducing agent may serve as a lead-in treatment to initiate the reduction of c-Myc prior to the administration of adjunct cancer therapeutic agents. This innovative approach modulates the disease state of c-Myc overexpressing cancers, making them less malignant and more susceptible to additional cancer therapies.

Career Highlights

Mark Lipstein is affiliated with Columbia University, where he continues to advance his research in cancer treatment. His dedication to innovation in this field has led to the development of groundbreaking therapies that have the potential to improve patient outcomes.

Collaborations

Mark has collaborated with notable colleagues, including Changchun Deng and Owen Anthony O'Connor. Their combined expertise contributes to the advancement of research in cancer therapies.

Conclusion

Mark Lipstein's innovative work in developing compounds to reduce c-Myc expression represents a significant advancement in cancer treatment. His contributions have the potential to change the landscape of therapies for hematological cancers, offering hope to many patients.